Epizyme Inc. (EPZM) Receives “Outperform” Rating from Leerink Swann
Epizyme Inc. (NASDAQ:EPZM)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Swann in a research report issued to clients and investors on Friday.
A number of other research firms have also recently issued reports on EPZM. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Mizuho reiterated a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research report on Monday, June 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 target price on shares of Epizyme in a research report on Monday, June 20th. JMP Securities reiterated a “buy” rating and issued a $28.00 target price on shares of Epizyme in a research report on Thursday, June 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Epizyme currently has an average rating of “Buy” and an average target price of $23.11.
Shares of Epizyme (NASDAQ:EPZM) traded down 1.37% during midday trading on Friday, hitting $9.39. 119,577 shares of the stock traded hands. The company’s market capitalization is $544.21 million. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.29. The stock has a 50 day moving average of $8.70 and a 200 day moving average of $10.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/epizyme-inc-epzm-receives-outperform-rating-from-leerink-swann.html
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative return on equity of 43.05% and a negative net margin of 5,174.49%. Equities research analysts predict that Epizyme will post ($2.20) earnings per share for the current fiscal year.
In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $10.37, for a total value of $41,480.00. Following the transaction, the insider now directly owns 35,538 shares of the company’s stock, valued at $368,529.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 25.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. HBK Investments L P bought a new position in Epizyme during the first quarter worth approximately $149,000. SECOR Capital Advisors LP bought a new position in Epizyme during the second quarter worth approximately $620,000. JPMorgan Chase & Co. raised its position in Epizyme by 550.8% in the first quarter. JPMorgan Chase & Co. now owns 153,656 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 130,044 shares in the last quarter. Renaissance Technologies LLC bought a new position in Epizyme during the first quarter worth approximately $356,000. Finally, Bank of New York Mellon Corp raised its position in Epizyme by 1.7% in the second quarter. Bank of New York Mellon Corp now owns 169,352 shares of the biopharmaceutical company’s stock worth $1,735,000 after buying an additional 2,866 shares in the last quarter. 80.79% of the stock is currently owned by institutional investors.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.